Vitalant - Donate Funds

Join us for Pittsburgh's 2022 NextUp Awards

Celebrating the Region's Young Volunteers

Learn more

The NextUp Awards, celebrating the area's youngest volunteers

HOW TO GIVE

WHO WE ARE

OUR IMPACT

As the nation’s largest independent, nonprofit organization focused exclusively on providing lifesaving blood services, Vitalant is uniquely positioned to become the nation’s most innovative and inclusive blood and biotherapies partner. Vitalant Foundation is the official fundraising arm of Vitalant.  

But our work doesn’t end with blood donation.

We also provide comprehensive transfusion medicine services and work on the cutting edge of blood science and healthcare. Vitalant Research Institute is world-renowned for scientific studies ranging from blood donor epidemiology to cellular therapy and virus discovery. Vitalant is an internationally known and respected leader that continues to push the boundaries to advance the experience, practice and application of transfusion medicine.

Financial gifts to Vitalant Foundation help ensure blood is available for patients in need and enhances research opportunities to support blood donors and recipients of the future.

Every day in the U.S., patients in hospitals, surgical centers and emergency treatment facilities need approximately:

29,000
units of red blood cells

5,000
units of platelets

6,500
units of plasma

The impact of blood donations is lifesaving, but the nation’s blood donor base continues to shrink. Financial gifts help address this challenge by funding critical donor recruitment initiatives and blood center operations. In addition to supporting the daily blood needs Vitalant meets, gifts also support research in donor and patient safety. Our Vitalant Research Institute leads the way in understanding new threats to blood safety and helps to find practical applications of new knowledge in transfusion biology. Recent research includes Vitalant’s involvement in work conducted at the onset of the COVID-19 pandemic to support patients with developing technology, as well as the ADVANCE study, which could lead to additional changes in blood donor eligibility.